Literature DB >> 26427793

Fibronectin Splicing Variants Containing Extra Domain A Promote Atherosclerosis in Mice Through Toll-Like Receptor 4.

Prakash Doddapattar1, Chintan Gandhi1, Prem Prakash1, Nirav Dhanesha1, Isabella M Grumbach1, Michael E Dailey1, Steven R Lentz1, Anil K Chauhan2.   

Abstract

OBJECTIVE: Cellular fibronectin containing extra domain A (EDA(+)-FN) is abundant in the arteries of patients with atherosclerosis. Several in vitro studies suggest that EDA(+)-FN interacts with Toll-like receptor 4 (TLR4). We tested the hypothesis that EDA(+)-FN exacerbates atherosclerosis through TLR4 in a clinically relevant model of atherosclerosis, the apolipoprotein E-deficient (Apoe(-/-)) mouse. APPROACH AND
RESULTS: The extent of atherosclerosis was evaluated in whole aortae and cross sections of the aortic sinus in male and female EDA(-/-)Apoe(-/-) mice (which lack EDA(+)-FN), EDA(fl/fl)Apoe(-/-) mice (which constitutively express EDA(+)-FN), and control Apoe(-/-) mice fed a high-fat Western diet for 14 weeks. Irrespective of sex, EDA(fl/fl)Apoe(-/-) mice exhibited a 2-fold increase in atherosclerotic lesions (aorta and aortic sinus) and macrophage content within plaques, whereas EDA(-/-)Apoe(-/-) mice exhibited reduced atherosclerotic lesions (P<0.05 versus Apoe(-/-), n=10-12 mice/group), although cholesterol and triglyceride levels and circulating leukocytes were similar. Genetic ablation of TLR4 partially reversed atherosclerosis exacerbation in EDA(fl/fl)Apoe(-/-) mice (P<0.05) but had no effect on atherosclerotic lesions in EDA(-/-)Apoe(-/-) mice. Purified cellular FN, which contains EDA, potentiated dose-dependent NFκB-mediated inflammation (increased phospho-NFκB p65/NFκB p65, tumor necrosis factor-α, and interleukin-1β) in bone marrow-derived macrophages from EDA(-/-)Apoe(-/-) mice but not from EDA(-/-)TLR4(-/-)Apoe(-/-) mice. Finally, using immunohistochemistry, we provide evidence for the first time that EDA(+)-FN colocalizes with macrophage TLR4 in murine aortic lesions and human coronary artery atherosclerotic plaques.
CONCLUSIONS: Our findings reveal that TLR4 signaling contributes to EDA(+)-FN-mediated exacerbation of atherosclerosis. We suggest that EDA(+)-FN could be a therapeutic target in atherosclerosis.
© 2015 The Authors.

Entities:  

Keywords:  TLR4; apolipoprotein E; atherosclerosis; cellular fibronectin EDA; macrophages

Mesh:

Substances:

Year:  2015        PMID: 26427793      PMCID: PMC4618710          DOI: 10.1161/ATVBAHA.115.306474

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  33 in total

1.  The EIIIA segment of fibronectin is a ligand for integrins alpha 9beta 1 and alpha 4beta 1 providing a novel mechanism for regulating cell adhesion by alternative splicing.

Authors:  Yung-Feng Liao; Philip J Gotwals; Victor E Koteliansky; Dean Sheppard; Livingston Van De Water
Journal:  J Biol Chem       Date:  2002-02-11       Impact factor: 5.157

2.  Relative distribution of fibronectin and type I, III, IV, V collagens in normal and atherosclerotic intima of human arteries.

Authors:  B V Shekhonin; S P Domogatsky; G L Idelson; V E Koteliansky; V S Rukosuev
Journal:  Atherosclerosis       Date:  1987-09       Impact factor: 5.162

3.  Fibronectin stimulates macrophage uptake of low density lipoprotein-heparin-collagen complexes.

Authors:  D J Falcone; B G Salisbury
Journal:  Arteriosclerosis       Date:  1988 May-Jun

4.  Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E.

Authors:  Kathrin S Michelsen; Michelle H Wong; Prediman K Shah; Wenxuan Zhang; Juliana Yano; Terence M Doherty; Shizuo Akira; Tripathi B Rajavashisth; Moshe Arditi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

5.  Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis.

Authors:  Michelle H Tan; Zhengwu Sun; Sarah L Opitz; Tracy E Schmidt; John H Peters; Elizabeth L George
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

6.  Extracellular matrix components in atherosclerotic arteries of Apo E/LDL receptor deficient mice: an immunohistochemical study.

Authors:  A Ström; E Ahlqvist; A Franzén; D Heinegård; A Hultgårdh-Nilsson
Journal:  Histol Histopathol       Date:  2004-04       Impact factor: 2.303

7.  Fibronectin and atherosclerosis.

Authors:  S Stenman; K von Smitten; A Vaheri
Journal:  Acta Med Scand Suppl       Date:  1980

8.  Lipoprotein-heparin-fibronectin-denatured collagen complexes enhance cholesteryl ester accumulation in macrophages.

Authors:  D J Falcone; N Mated; H Shio; C R Minick; S D Fowler
Journal:  J Cell Biol       Date:  1984-10       Impact factor: 10.539

9.  Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan.

Authors:  Andres F Muro; Anil K Chauhan; Srecko Gajovic; Alessandra Iaconcig; Fabiola Porro; Giorgio Stanta; Francisco E Baralle
Journal:  J Cell Biol       Date:  2003-07-07       Impact factor: 10.539

10.  Expression of extra domain A fibronectin sequence in vascular smooth muscle cells is phenotype dependent.

Authors:  M A Glukhova; M G Frid; B V Shekhonin; T D Vasilevskaya; J Grunwald; M Saginati; V E Koteliansky
Journal:  J Cell Biol       Date:  1989-07       Impact factor: 10.539

View more
  30 in total

1.  Smooth muscle cell-specific fibronectin-EDA mediates phenotypic switching and neointimal hyperplasia.

Authors:  Manish Jain; Nirav Dhanesha; Prakash Doddapattar; Mehul R Chorawala; Manasa K Nayak; Anne Cornelissen; Liang Guo; Aloke V Finn; Steven R Lentz; Anil K Chauhan
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

Review 2.  Sex as a Biological Variable in Atherosclerosis.

Authors:  Joshua J Man; Joshua A Beckman; Iris Z Jaffe
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

3.  Integrin α4β1 and TLR4 Cooperate to Induce Fibrotic Gene Expression in Response to Fibronectin's EDA Domain.

Authors:  Rhiannon M Kelsh-Lasher; Anthony Ambesi; Ceyda Bertram; Paula J McKeown-Longo
Journal:  J Invest Dermatol       Date:  2017-08-24       Impact factor: 8.551

Review 4.  Danger-Associated Molecular Patterns Derived From the Extracellular Matrix Provide Temporal Control of Innate Immunity.

Authors:  Charles W Frevert; Jessica Felgenhauer; Malgorzata Wygrecka; Madalina V Nastase; Liliana Schaefer
Journal:  J Histochem Cytochem       Date:  2018-01-01       Impact factor: 2.479

5.  Fibronectin Containing Extra Domain A Induces Plaque Destabilization in the Innominate Artery of Aged Apolipoprotein E-Deficient Mice.

Authors:  Prakash Doddapattar; Manish Jain; Nirav Dhanesha; Steven R Lentz; Anil K Chauhan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-11       Impact factor: 8.311

Review 6.  Targeting toll-like receptor 4 signalling pathways: can therapeutics pay the toll for hypertension?

Authors:  Kenia Pedrosa Nunes; Amanda Almeida de Oliveira; Francesca Elisabeth Mowry; Vinicia Campana Biancardi
Journal:  Br J Pharmacol       Date:  2018-08-09       Impact factor: 8.739

7.  Differential Roles of Endothelial Cell-Derived and Smooth Muscle Cell-Derived Fibronectin Containing Extra Domain A in Early and Late Atherosclerosis.

Authors:  Prakash Doddapattar; Rishabh Dev; Manish Jain; Nirav Dhanesha; Anil K Chauhan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-05-21       Impact factor: 8.311

8.  Endothelial FN (Fibronectin) Deposition by α5β1 Integrins Drives Atherogenic Inflammation.

Authors:  Zaki Al-Yafeai; Arif Yurdagul; Jonette M Peretik; Mabruka Alfaidi; Patrick A Murphy; A Wayne Orr
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-11       Impact factor: 8.311

Review 9.  Fibronectin maintains the balance between hemostasis and thrombosis.

Authors:  Yiming Wang; Heyu Ni
Journal:  Cell Mol Life Sci       Date:  2016-04-21       Impact factor: 9.261

10.  Targeting Myeloid-Specific Integrin α9β1 Improves Short- and Long-Term Stroke Outcomes in Murine Models With Preexisting Comorbidities by Limiting Thrombosis and Inflammation.

Authors:  Nirav Dhanesha; Manish Jain; Amit K Tripathi; Prakash Doddapattar; Mehul Chorawala; Girish Bathla; Manasa K Nayak; Madankumar Ghatge; Steven R Lentz; Shigeyuki Kon; Anil K Chauhan
Journal:  Circ Res       Date:  2020-03-20       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.